Livzon Pharmaceutical Gets China Trial Clearance for Two Drug Candidates

MT Newswires Live
10/27

Livzon Pharmaceutical Group (HKG:1513) said China's National Medical Products Administration approved clinical trials for two drug candidates.

One candidate, Tiange Dingxuan Granules, is a traditional Chinese medicine being developed to treat vestibular migraine, which can cause recurring dizziness and vertigo, according to Tuesday Hong Kong bourse filings. The other, an experimental antibody, is being developed to prevent blood clots following total knee arthroplasty.

Both products must undergo clinical trials and further regulatory review before they can be marketed, the drugmaker said.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10